Evidence map›Paper›PMID 32226787›Full record

ReviewFrontiers in cell and developmental biology2020

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Challenges in Clinical Applications.

Austin Gowen, Farah Shahjin, Subhash Chand, Katherine E Odegaard, Sowmya V Yelamanchili

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 5 pooled it
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

210 citing papers in PubMed, 5 syntheses or guidelines pooled it, 319 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Integrative Approaches to Treating Cellular Senescence in Kidney Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

150 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Austin GowenDepartment of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, United States.
Farah ShahjinDepartment of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, United States.
Subhash ChandDepartment of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, United States.
Katherine E OdegaardDepartment of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, United States.
Sowmya V YelamanchiliDepartment of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, United States.
University of Nebraska Medical Center · US

Funding

Extracellular vesicles, meth relapse and sex differencesR01DA046852 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BEVINS, RICK A, PENDYALA, GURUDUTT · 2018 to 2022
$2.4M
Role of extracellular vesicles in methamphetamine mediated neurotoxicityR01DA042379 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI YELAMANCHILI, SOWMYA · 2016 to 2020
$1.9M
Role of extracellular vesicles in methamphetamine and HIV induced neurotoxicityR21DA046855 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KASHANCHI, FATAH, YELAMANCHILI, SOWMYA · 2018 to 2019
$436k
NIDA NIH HHS R01 DA042379NIDA NIH HHS R01 DA046852NIDA NIH HHS R21 DA046855
6 · The paper itself

Abstract

Stem cell therapy has garnered much attention and application in the past decades for the treatment of diseases and injuries. Mesenchymal stem cells (MSCs) are studied most extensively for their therapeutic roles, which appear to be derived from their paracrine activity. Recent studies suggest a critical therapeutic role for extracellular vesicles (EV) secreted by MSCs. EV are nano-sized membrane-bound vesicles that shuttle important biomolecules between cells to maintain physiological homeostasis. Studies show that EV from MSCs (MSC-EV) have regenerative and anti-inflammatory properties. The use of MSC-EV, as an alternative to MSCs, confers several advantages, such as higher safety profile, lower immunogenicity, and the ability to cross biological barriers, and avoids complications that arise from stem cell-induced ectopic tumor formation, entrapment in lung microvasculature, and immune rejection. These advantages and the growing body of evidence suggesting that MSC-EV display therapeutic roles contribute to the strong rationale for developing EV as an alternative therapeutic option. Despite the success in preclinical studies, use of MSC-EV in clinical settings will require careful consideration; specifically, several critical issues such as (i) production methods, (ii) quantification and characterization, (iii) pharmacokinetics, targeting and transfer to the target sites, and (iv) safety profile assessments need to be resolved. Keeping these issues in mind, the aim of this mini-review is to shed light on the challenges faced in MSC-EV research in translating successful preclinical studies to clinical platforms.

Indexed as

biodistributionclinical useextracellular vesiclemesenchym stem cellstem cell therapeutics

Identifiers

PMID32226787
PMCPMC7080981
OpenAlexW3011116178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.